Voss Capital LP bought a new stake in shares of Actuate Therapeutics (NASDAQ:ACTU - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 55,246 shares of the company's stock, valued at approximately $440,000. Voss Capital LP owned 0.28% of Actuate Therapeutics as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Envestnet Asset Management Inc. bought a new position in Actuate Therapeutics during the fourth quarter valued at about $83,000. BIOS Capital Management LP acquired a new position in shares of Actuate Therapeutics during the fourth quarter worth approximately $78,753,000. Freestone Capital Holdings LLC bought a new stake in shares of Actuate Therapeutics during the fourth quarter valued at approximately $80,000. Finally, Sigma Planning Corp bought a new stake in shares of Actuate Therapeutics during the fourth quarter valued at approximately $128,000.
Analysts Set New Price Targets
Several research firms have issued reports on ACTU. Craig Hallum assumed coverage on Actuate Therapeutics in a report on Tuesday. They set a "buy" rating and a $21.00 price objective on the stock. HC Wainwright started coverage on Actuate Therapeutics in a research report on Monday, March 17th. They set a "buy" rating and a $20.00 target price for the company.
Get Our Latest Stock Analysis on ACTU
Actuate Therapeutics Stock Up 0.4 %
Shares of NASDAQ ACTU traded up $0.04 during mid-day trading on Thursday, hitting $9.04. The company's stock had a trading volume of 48,030 shares, compared to its average volume of 46,758. The company's fifty day simple moving average is $7.42 and its 200-day simple moving average is $8.06. Actuate Therapeutics has a one year low of $5.51 and a one year high of $11.73.
About Actuate Therapeutics
(
Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Featured Articles
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
